The pathway through LC-MS method development: in-house or ready-to-use kit-based methods?
Abstract Historically, the determination of low concentration analytes was initially made possible by the development of rapid and easy-to-perform immunoassays (IAs). Unfortunately, typical problems inherent to IA technologies rapidly appeared (e.g. elevated cost, cross-reactivity, lot-to-lot variability, etc.). In turn, liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are sensitive and specific enough for such analyses. Therefore, they would seem to be the most promising candidates to replace IAs. There are two main choices when implementing a new LC-MS/MS method in a clinical laboratory: (1) Developing an in-house method or (2) purchasing ready-to-use kits. In this paper, we discuss some of the respective advantages, disadvantages and mandatory requirements of each choice. Additionally, we also share our experiences when developing an in-house method for cortisol determination and the implementation of an “ready-to-use” (RTU) kit for steroids analysis..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
---|---|
Enthalten in: |
Clinical chemistry and laboratory medicine - 58(2020), 6 vom: 18. Feb., Seite 1002-1009 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Le Goff, Caroline [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: |
---|
Anmerkungen: |
©2020 Walter de Gruyter GmbH, Berlin/Boston |
---|
doi: |
10.1515/cclm-2019-0916 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
GRUY00715917X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | GRUY00715917X | ||
003 | DE-627 | ||
005 | 20230811134129.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230811s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1515/cclm-2019-0916 |2 doi | |
035 | |a (DE-627)GRUY00715917X | ||
035 | |a (DE-B1597)cclm-2019-0916-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |a 610 |q VZ |
082 | 0 | 4 | |a 540 |a 610 |q VZ |
084 | |a 15,3 |2 ssgn | ||
084 | |a PHARM |q DE-84 |2 fid | ||
084 | |a 44.46 |2 bkl | ||
100 | 1 | |a Le Goff, Caroline |e verfasserin |4 aut | |
245 | 1 | 0 | |a The pathway through LC-MS method development: in-house or ready-to-use kit-based methods? |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a ©2020 Walter de Gruyter GmbH, Berlin/Boston | ||
520 | |a Abstract Historically, the determination of low concentration analytes was initially made possible by the development of rapid and easy-to-perform immunoassays (IAs). Unfortunately, typical problems inherent to IA technologies rapidly appeared (e.g. elevated cost, cross-reactivity, lot-to-lot variability, etc.). In turn, liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are sensitive and specific enough for such analyses. Therefore, they would seem to be the most promising candidates to replace IAs. There are two main choices when implementing a new LC-MS/MS method in a clinical laboratory: (1) Developing an in-house method or (2) purchasing ready-to-use kits. In this paper, we discuss some of the respective advantages, disadvantages and mandatory requirements of each choice. Additionally, we also share our experiences when developing an in-house method for cortisol determination and the implementation of an “ready-to-use” (RTU) kit for steroids analysis. | ||
700 | 1 | |a Farre-Segura, Jordi |4 aut | |
700 | 1 | |a Stojkovic, Violeta |4 aut | |
700 | 1 | |a Dufour, Patrice |4 aut | |
700 | 1 | |a Peeters, Stéphanie |4 aut | |
700 | 1 | |a Courtois, Justine |4 aut | |
700 | 1 | |a Nizet, Adrien |4 aut | |
700 | 1 | |a De Vos, Nathalie |4 aut | |
700 | 1 | |a Cavalier, Etienne |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d De Gruyter, 1998 |g 58(2020), 6 vom: 18. Feb., Seite 1002-1009 |h Online-Ressource |w (DE-627)GRUY000051497 |w (DE-600)1492732-9 |w (DE-576)088704882 |x 1437-4331 |7 nnns |
773 | 1 | 8 | |g volume:58 |g year:2020 |g number:6 |g day:18 |g month:02 |g pages:1002-1009 |
856 | 4 | 0 | |u https://dx.doi.org/10.1515/cclm-2019-0916 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_GRUY | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
936 | b | k | |a 44.46 |j Klinische Pathologie |q VZ |
951 | |a AR | ||
952 | |d 58 |j 2020 |e 6 |b 18 |c 02 |h 1002-1009 |